March 3, 2016Open Access
View Full PaperDapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
Key Points
Key points are not available for this paper at this time.
Abstract
Dapagliflozin was effective in lowering albuminuria in patients with T2DM and hypertension using renin-angiotensin system blockade therapy. Reductions in albuminuria were still present after adjusting for changes in HbA1c, SBP, body weight and eGFR. Dapagliflozin-induced improvements in glycaemic control and reductions in SBP, coupled with other potentially beneficial renal effects, may lead to a reduced long-term renal and cardiovascular risk.